NVAX NOVAVAX INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1000694 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-61.3%
TTM net income YoY-122.5%
TTM EPS YoY-125.9%
Revenue 3-yr CAGR-26.8%
Net income 3-yr CAGR—
Margins
Gross margin78.0%
Operating margin-21.2%
Net margin-18.6%
FCF margin-59.2%
EBITDA margin-17.7%
Returns
ROE—
ROA-7.4%
ROIC (approx.)—
Asset turnover0.40x
Leverage & solvency
Liabilities / assets124.4%
Debt / equity—
Current ratio2.15x
Interest coverage-4.01x
Cash quality & payout
Operating cash flow / net income3.11x
Accruals ratio15.7%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $68.30M | $56.70M | $139.51M | $147.14M | $70.44M | $239.24M | $666.65M | $88.31M |
| Cost of revenue | $23.49M | $14.25M | $30.70M | $22.10M | $21.50M | $15.32M | $14.12M | $36.67M |
| Gross profit | $44.81M | $42.45M | $108.82M | $125.03M | $48.95M | $223.91M | $652.54M | $51.64M |
| R&D expense | $52.45M | $70.69M | $95.47M | $75.88M | $98.27M | $79.23M | $88.94M | $104.38M |
| SG&A expense | $23.64M | $26.66M | $28.78M | $34.12M | $31.66M | $43.61M | $48.09M | $78.34M |
| Operating income | -$31.28M | -$54.91M | -$15.43M | $14.23M | -$178.02M | $101.07M | $515.51M | -$131.08M |
| Interest expense | $5.40M | $5.69M | $4.90M | $5.82M | $5.48M | $5.52M | $5.72M | $7.58M |
| Pretax income | -$29.65M | -$51.68M | -$8.51M | $17.90M | -$203.04M | $107.45M | $519.85M | -$73.58M |
| Income tax | $1.72M | $1.71M | $985,000 | $376,000 | -$657,000 | $946,000 | $1.20M | $7.45M |
| Net income | -$31.38M | -$53.39M | -$9.49M | $17.53M | -$202.38M | $106.51M | $518.65M | -$81.03M |
| EBITDA | -$28.23M | -$51.85M | -$12.37M | $19.74M | -$171.43M | $108.63M | $523.85M | -$119.06M |
| EPS (basic) | -0.19 | -0.32 | -0.06 | — | -1.25 | 0.66 | 3.22 | — |
| EPS (diluted) | -0.19 | -0.32 | -0.06 | — | -1.25 | 0.62 | 2.93 | — |
| Weighted avg. shares (diluted) | 164.92M | 164.57M | 163.28M | — | 162.35M | 177.22M | 177.62M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $222.46M | $191.46M | $228.36M | $240.63M | $283.36M | $268.98M | $278.48M | $545.29M |
| Short-term investments | $399.91M | $527.88M | $561.97M | $494.45M | $494.87M | $358.56M | $468.14M | $392.89M |
| Inventory | $18.50M | $10.01M | $11.46M | $11.54M | $13.51M | $10.24M | $10.26M | $8.75M |
| Current assets | $707.96M | $771.10M | $850.82M | $978.28M | $974.59M | $919.51M | $868.03M | $1.13B |
| PP&E, net | $36.28M | $38.13M | $42.15M | $44.80M | $49.12M | $129.64M | $133.54M | $138.41M |
| Goodwill | $112.08M | $112.54M | $112.89M | $113.46M | $113.08M | $112.96M | $112.03M | $107.48M |
| Total assets | $888.00M | $955.58M | $1.04B | $1.18B | $1.18B | $1.34B | $1.29B | $1.56B |
| Current liabilities | $329.85M | $330.57M | $342.46M | $459.95M | $429.87M | $389.14M | $422.17M | $1.15B |
| Long-term debt | $292.09M | $291.49M | $291.04M | $244.21M | — | — | — | — |
| Total debt | $292.09M | $291.49M | $291.04M | $244.21M | — | — | — | — |
| Total liabilities | $1.10B | $1.15B | $1.19B | $1.30B | $1.34B | $1.30B | $1.37B | $2.18B |
| Shareholders' equity | -$216.85M | -$190.71M | -$144.76M | -$127.75M | -$156.67M | $37.62M | -$75.64M | -$623.84M |
| Net debt | $69.63M | $100.03M | $62.68M | $3.58M | — | — | — | — |
| Shares outstanding | 164.99M | 164.82M | 164.42M | 162.58M | 162.47M | 162.16M | 161.96M | 160.42M |
| Cash flow statement | ||||||||
| Operating cash flow | -$94.24M | -$72.81M | -$32.42M | -$39.48M | $107.80M | -$127.46M | -$185.50M | -$173.16M |
| Capital expenditure | $1.02M | $588,000 | $1.27M | $2.08M | $2.02M | $527,000 | $1.59M | $1.93M |
| Free cash flow | -$95.26M | -$73.39M | -$33.69M | -$41.55M | $105.79M | -$127.99M | -$187.10M | -$175.09M |
| Investing cash flow | $127.78M | $34.90M | -$28.36M | $20.48M | -$136.53M | $111.10M | -$73.32M | $144.01M |
| Financing cash flow | -$2.00M | $1.20M | $37.67M | -$6.60M | $42.44M | -$1.04M | -$7.06M | -$3.42M |
| Depreciation & amortization | $3.05M | $3.06M | $3.06M | $5.51M | $6.58M | $7.56M | $8.34M | $12.02M |
| Stock-based compensation | $7.96M | $8.09M | $7.72M | $7.97M | $8.55M | $9.21M | $10.29M | $10.45M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.